Factors Influencing CLL Treatment Decisions
- Chronic lymphocytic leukemia (CLL) treatment decisions today hinge on multiple factors — disease aggressiveness, lifestyle fit, infection risk, and whether a patient prefers time‑limited therapy over ongoing treatment.
- “It’s quite a complicated conversation,” says Dr. Kieron Dunleavy at MedStar Georgetown University Hospital at the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., noting that choices must balance effectiveness, toxicity, and a patient’s personal priorities.
- Newer treatment options — including fixed‑duration venetoclax‑based regimens and emerging BTK/BCL‑2 inhibitor combinations — give patients more flexibility, shifting the focus from simply finding an effective therapy to finding the right one for their goals and tolerance.
One of the biggest shifts in how chronic lymphocytic leukemia (CLL) is treated today isn’t just which drugs are used; it’s how long patients stay on them.
Deciding on the right approach for an individual patient is “quite a complicated conversation,” Dr. Kieron Dunleavy, a hematologist-oncologist with MedStar Georgetown University Hospital at the Georgetown Lombardi Comprehensive Cancer Center, tells SurvivorNet.
Read MoreThe Factors That Go Into the CLL Treatment Decision-Making
Dr. Dunleavy describes several factors that he and his patients weigh together when choosing a treatment approach:- How aggressive the disease is and what symptoms it’s causing. The clinical picture of a patient’s CLL is often the starting point for any treatment conversation.
- The logistics of therapy. Many CLL treatments today can be taken orally, which most patients prefer over intravenous (IV) infusions. “They’re usually happier if they can have an oral medication rather than an intravenous medication,” Dr. Dunleavy says, though some strategies combine oral and intravenous components.
- Whether the patient wants time-limited therapy. This has become one of the most important considerations for many patients.
- Infection risk. Some regimens carry a higher risk of certain infections, which can be a particularly important consideration for older patients or those with other underlying health conditions.
What Is Time-Limited Therapy?
Unlike some cancer treatments that continue indefinitely, certain CLL regimens are designed to be given for a fixed, defined period of time after which treatment stops, ideally with the disease in remission.Dr. Dunleavy says the best-established time-limited approach combines venetoclax (Venclexta), a BCL-2 inhibitor, with obinutuzumab (Gazyva), an antibody therapy, for previously untreated patients. “In newly diagnosed patients with CLL or previously untreated patients with CLL, when they do need treatment, we can offer time-limited approaches,” Dr. Dunleavy explains.
Newer combinations are also emerging that extend this fixed-duration concept beyond venetoclax and obinutuzumab, including combinations that pair a BTK inhibitor with a BCL-2 inhibitor for newly diagnosed patients. Dr. Dunleavy and other CLL specialists are gaining more experience with these approaches through ongoing clinical trials.
“We will often have patients who really, really want time-limited therapy, and that factors into the conversation,” he explains.
Expert Resources for CLL Patients
- CLL Treatment Decision Making — Exploring All Your Options To Find What’s Right For You
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- CLL is Not Considered Curable So Treatment May Resume Years Later
- ‘The Eye of the Tiger’ — Why Mindset and Lifestyle are So Important During Treatment for CLL
- ‘Game Changing’ New Treatment Gives Hope to Relapsed CLL Patients
The Trade-Off: Effectiveness vs. Toxicity
Dr. Dunleavy says combining multiple targeted agents can offer a theoretical advantage that hits the disease through more than one pathway at once. However, he says this comes with trade-offs.
“It’s great that you’re getting the benefit of being able to target different pathways, but that typically comes with an increased risk of toxicity as well,” he says. “So not all patients might be able to tolerate these combinations.”
Much of the current clinical trial work in CLL is focused on finding combinations that maximize effectiveness while keeping side effects low.
Sequencing vs Combining Therapies
Another open question in the field is whether it’s better to give two targeted therapies together upfront, or to use one first and save the second for if the disease returns.
“If you get two targeted agents together, you’re targeting pathway A and pathway B,” Dr. Dunleavy explains. “Is that better than having one targeted agent and then being able to use the other targeted agent if the disease comes back? Some of these questions we don’t have the answers to.”
Researchers also use measurable residual disease (MRD) testing (a small number of nearly undetectable cancer cells found after treatment) in clinical trials to better understand how completely these therapies clear CLL, and to study resistance mutations to understand why treatments eventually stop working and how that might be overcome in the future.
The Takeaway for Patients: ‘Finding the Right Treatment Option’
Despite the complexity, Dr. Dunleavy is emphatic about how far CLL treatment has come.
“When I compare that to a long time ago when we used chemotherapy approaches, we’re in a much, much better place now with agents that are much more highly effective and much less toxic,” he says.
For patients, that means treatment decisions today are less about finding any effective option and more about finding the right option — one that fits their disease, their life, and their preferences around treatment duration and side effects.
Learn more about SurvivorNet's rigorous medical review process.
